Shares of NRx Pharmaceuticals (NASDAQ:NRXP) jumped 11.8% as of the market close on Wednesday. The big gain came after the company announced positive safety findings from a late-stage study evaluating its drug Zyesami in combination with Gilead Sciences’Veklury in treating hospitalized patients with acute respiratory failure due to COVID-19.
NRx didn’t provide details from the late-stage study of Zyesami and Veklury. However, the company stated that the study’s Data Safety Monitoring Board has identified no new safety issues and is recommending moving forward with enrollment in the trial.
g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/639868/covid-19-coronavirus-wood-blocks.jpg&w=1000&op=resize 1000w, g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/639868/covid-19-coronavirus-wood-blocks.jpg&w=2000&op=resize 2000w”/>
Image source: Getty Images.
That was enough for investors to drive the biotech stock higher today. NRx reported results from a phase 2b/3 study in July that found that Zyesami helped prevent cytokine storms in COVID-19 patients. Cytokine storms occur when the body produces too many cytokine proteins, which can result in serious organ damage.
Although the update from NRx was good news, the big milestone that investors are waiting for is U.S. Emergency Use Authorization (EUA) for Zyesami. NRx submitted its EUA filing on May 31, 2021.
This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.